PALI
Palisade Bio, Inc.1.7200
-0.0900-4.97%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
256.63MP/E (TTM)
-Basic EPS (TTM)
-2.07Dividend Yield
0%Recent Filings
10-K
FY2025 results
Palisade Bio posted a $16.8M net loss for FY2025 ended December 31, 2025, up 16% y/y, driven by $10.2M R&D (up 12%) and $7.9M G&A (up 36%), offset by $1.3M other income. R&D ramped with Phase 1 PALI-2108 completion—dosing 89 healthy volunteers and 5 UC patients met safety/PK endpoints, all UC patients responded—while Q4 kicked off exploratory Phase 1b FSCD cohort, triggering first Giiant milestone payment. October's $128M raise swelled cash to $133M, fueling Q4 hiring and trial acceleration. Q4 margins held as clinical momentum built. Yet clinical delays lurk.
8-K
Authorized shares hiked 20M
Palisade Bio stockholders approved increasing authorized common shares from 280 million to 300 million at the December 3, 2025 special meeting, effective immediately via Delaware filing. This supports issuing up to 8.6 million shares underlying July 2025 warrants, ratified under Nasdaq rules with 104.7 million votes for. Flexibility gained. Yet broker non-votes hit 22.4 million.
10-Q
Q3 FY2025 results
Palisade Bio narrowed its Q3 operating loss to $2.9M from $3.6M y/y, as R&D expenses dropped 35% to $1.4M amid PALI-2108 Phase 1 progress and lower joint development costs with Giiant, while G&A edged up 5%. YTD through September 30, 2025, operating loss shrank 30% to $8.1M from $11.5M y/y, with cash burn at $7.7M from operations versus $9.8M prior year; cash ended at $5.2M, bolstered by $3.9M warrant exercise proceeds, plus $138M October equity offering. Diluted EPS improved to $(0.38) from $(2.32) y/y, reconciling to 7.5M weighted shares. No debt beyond $0.2M insurance financing. Warrant approvals pending. Clinical delays could stall PALI-2108 momentum.
8-K
Phantom plan terminated abruptly
8-K
Stockholders approve reverse split
Palisade Bio stockholders elected J.D. Finley, Donald Williams, and Emil Chuang as directors at the October 17, 2025 annual meeting, with 39% turnout. They ratified Baker Tilly US as auditors for 2025. Crucially, they approved a board-discretionary reverse stock split (1-for-5 to 1-for-50) by year-end. Board holds the trigger.
CADL
Candel Therapeutics, Inc.
5.74-0.03
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
EDSA
Edesa Biotech, Inc.
1.49-0.00
GRI
GRI Bio, Inc.
0.48+0.00
JBIO
Jade Biosciences, Inc.
16.04+0.79
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
KRRO
Korro Bio, Inc.
8.22+0.26
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
PTNT
Palatin Technologies, Inc.
22.82+8.33